IP Library Granted Patent US 10,725,029
Granted Patent B2
US 10,725,029 · App. 15/786,755 · Granted Jul 28, 2020

Kit for in vitro or ex vivo measurement of SCD127 expression in a biological sample

Inventors: Alain Lepape (Saint-Genis-Laval, FR); Fabienne Venet (Beynost, FR); Astrid Villars (Lyons, FR); Guillaume Monneret (Lyons, FR)
Assignees: HOSPICES CIVILS DE LYON; BIOMERIEUX
G01N33/54306B29B15/08B29C35/0266B29C70/16B29C70/384B29C70/54C08J5/24G01N33/53G01N33/6893G01N33/96B29C53/582B29C2035/0211B29K2101/10B29K2105/243G01N2333/7155G01N2800/26G01N2800/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,725,029
App. No.
15/786,755
Granted
Jul 28, 2020
Kind
B2
Abstract

A kit for in vitro or ex vivo measurement of sCD127 expression in a biological sample, the kit including: specific tools or reagents allowing measurement of sCD127 expression in said biological sample; and a positive standard sample which is a sample calibrated to contain an amount of sCD127 which corresponds to the mean amount measured in a pool of samples from patients who are known to have developed a nosocomial infection, and/or a negative standard sample which is a sample calibrated to contain the amount of sCD127 which corresponds to the mean amount measured in a pool of samples from patients who are known not to have developed a nosocomial infection.

Claims (13)

1. A kit for in vitro or ex vivo measurement of solubleCD127 expression in a biological sample, the kit comprising:

tools or reagents allowing measurement of solubleCD127 expression in said biological sample; and

a positive standard sample which is a sample calibrated to contain an amount of solubleCD127 which corresponds to the mean amount measured in a pool of samples from patients who are patients hospitalized in intensive care and/or having sustained an insult, generating a systemic inflammatory response called SIRS, and who are known to have developed a nosocomial infection, and/or a negative standard sample which is a sample calibrated to contain the amount of solubleCD127 which corresponds to the mean amount measured in a pool of samples from patients who are patients hospitalized in intensive care and/or having sustained an insult, generating a systemic inflammatory response called SIRS, and who are known not to have developed a nosocomial infection.

2. The kit according to claim 1 , wherein said tools or reagents allow a detection and/or a quantification of solubleCD127 expression.

3. The kit according to claim 2 , wherein said tools or reagents allow the detection and/or the quantification of solubleCD127 expression at a protein level.

4. The kit according to claim 3 , wherein said tools or reagents are anti-solubleCD127 antibodies.

5. The kit according to claim 3 , wherein said tools or reagents are monoclonal anti-solubleCD127 antibodies.

6. The kit according to claim 1 , wherein said patients are patients with sepsis or severe sepsis.

7. The kit according to claim 1 , wherein said patients are patients in septic shock.

8. The kit according to claim 7 , wherein said biological samples of the pool are taken within 10 days, or at day 10 after septic shock.

9. The kit according to claim 7 , wherein said biological samples of the pool are taken within 7 days, or at day 7 after septic shock.

10. The kit according to claim 7 , wherein said biological samples of the pool are taken within 4 days, or at day 4 after septic shock.

11. The kit according to claim 7 , wherein said biological samples of the pool are taken within 3 days, or at day 3 (D3) after septic shock.

Priority Claims (1)
FR 12 52641 · Mar 23, 2012 · national
Continuity (2)
Division 14387071
Related Publication 20180111342A1 · Apr 26, 2018